logo-loader
viewGenprex, Inc.

Full interview: Genprex's active drug ingredient validated by independent medical journal 'Nature Medicine'

Genprex (NASDAQ:GNPX) CEO Rodney Varner tells Proactive that the active ingredient in the biotech firm's immunogene therapy Oncoprex has been shown to prevent tumor growth in triple-negative breast cancer patients by an independent researcher.

Varner notes the study was published in the medical Journal “Nature Medicine”, a widely respected publication in the medical community, where he says researchers found that the gene TUSC2, the lead component of the drug, acts as a tumor-preventing gene.

Quick facts: Genprex, Inc.

Price: 0.443 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $7.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genprex Inc making progress on branding for its lead cancer therapy, Oncoprex

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the biotech has initiated the first phase of branding for its lead drug candidate, Oncoprex, an immunogene therapy to treat non-small cell lung cancer. Varner says the Texas-based company has completed the creation and submission of...

on 08/06/2019

2 min read